Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of $137.91K could theoretically repay 0% of its total liabilities ($7.36 Million) in one year. See free cash flow generation of Drugs Made In America Acquisition Corp. to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2024–2024)
Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Ordinary Shares across 1 annual periods. See financial agility of Drugs Made In America Acquisition Corp. to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2024)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Ordinary Shares. For market capitalisation and broader financial context, see market cap of Drugs Made In America Acquisition Corp. .
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -216.50x | $-172.26K | $795.67 | — |